In the article that accompanies this editorial, Levis et al 11 report that post-transplant maintenance therapy with the FLT3 inhibitor gilteritinib improves outcomes in adults in remission ...

The ASAP trial sets new perspectives on international therapy standards: High-dose chemotherapy is not always necessary before transplantation in cases of acute myeloid leukemia (AML). This means ...

Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...